Serum, synovial and mRNA expression of interleukin-33 in juvenile idiopathic arthritis patients: Potential role as a marker of disease activity and relation to musculoskeletal ultrasound
-
Published:2020-07
Issue:3
Volume:42
Page:225-230
-
ISSN:1110-1164
-
Container-title:The Egyptian Rheumatologist
-
language:en
-
Short-container-title:The Egyptian Rheumatologist
Author:
Noor-eldeen Enas,
Hassan Waleed A.ORCID,
Behiry Eman G.ORCID,
El-monem Abd El-hameed Abd
Reference39 articles.
1. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis;Ringold;Arthritis Rheumatol,2019
2. Juvenile Idiopathic Arthritis for the Pediatric Orthopedic Surgeon;Bovid;Orthop Clin North Am,2019
3. Tumor necrosis factor-α-308 A/G gene polymorphism in children with juvenile idiopathic arthritis: relation to disease activity, damage, and functional status;El Gazzar;Clin Rheumatol,2017
4. Omega-3 fatty acids in juvenile idiopathic arthritis: effect on cytokines (IL-1 and TNF-α), disease activity and response criteria;Gheita;Clin Rheumatol,2012
5. Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity;Gheita;Joint Bone Spine,2012